Participant flow

Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery · Source last updated 2023-08-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. RADIATION THERAPY: Beginning week 10, patients undergo 3 fractions of brachytherapy or IMRT over 3 weeks. Patients then undergo EBRT QD 5 days a week for 5 weeks. Gemcitabine Hydrochloride: Given IV Docetaxel: Given IV Internal Radiation Therapy: Undergo brachytherapy Intensity-Modulated Radiation Therapy: Undergo IMRT External Beam Radiation Therapy: Undergo EBRT Laboratory Biomarker Analysis: Correlative studies

   id

   FG000

   title

   Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT/EBRT)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Three participants were enrolled into the study between 9/17/2013 and 6/17/2014.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice